Alpha-9 Oncology doses first subject in phase 1 study for new melanoma diagnostic agent
Source: Healio, May 2024
Key takeaways:
- Alpha-9 Oncology has dosed the first participant in its study evaluating Ga-A9-3202 for the imaging of melanoma.
- Ga-A9-3202 is a radiodiagnostic that targets the melanocortin 1 receptor.
The first participant has been dosed in the phase 1 study evaluating Ga-A9-3202 for locally advanced or metastatic melanoma imaging, Alpha-9 Oncology announced in a press release.
Ga-A9-3202 is a radiodiagnostic that targets the melanocortin 1 receptor (MC1R). The expression of this receptor is known to be elevated in malignant melanoma and other types of skin cancers, positioning Ga-A9-3202 as a promising imaging agent.